{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"To determine the median overall survival based on an intent-to-treat analysis, which should exceed 10 years, based on the projected 10-year survival of Total Therapy III, keeping in mind that participants are included in this protocol with up to 12 months of prior therapy.","groups":[{"description":"This was a single arm study for myeloma patients with \\<12 months of prior treatment to determine whether the incorporation of bortezomib into a tandem transplant regimen followed by 2 years of maintenance therapy would increase event-free survival.","id":"OG000","title":"Tandem Transplant in MM <12 Mos of Prior Treatment"}],"populationDescription":"Enrollment halted prematurely. Study met stopping rules (3 or more of the first 20 participants died due to treatment-related toxicity).\n\nData for outcome measure 4 were not collected.","reportingStatus":"POSTED","timeFrame":"10 years","title":"Overall Survival","type":"SECONDARY"}